Leukemia, Lymphoid: all 1,772 studies
Page 10 of 18. Open to participants first (173), then studies with results posted, then the rest; newest registration first within each.
- Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and IrelandCompletedNCT03582098
- Postural Control Under Different Cognitive Loads in Adult Survivors of Acute Lymphoblastic Leukemia and Age-Matched Healthy IndividualsCompletedNCT03581045
- CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
- CD19-CAR-T Cells in Patients With R/R B-ALLStatus unknownNCT03574168Phase 1
- Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALLStatus unknownNCT03564704Phase 2/3
- Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALLCompletedNCT03559413Phase 1/2
- Childhood Acute Lymphoblastic Leukaemia: Follow-UpCompletedNCT03545659
- Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC StudyCompletedNCT03545035
- CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）Status unknownNCT03544021Phase 1/2
- The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With IbrutinibCompletedNCT03528941
- EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute LeukemiaTerminatedNCT03519984Phase 1
- A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"WithdrawnNCT03515785
- Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic LeukemiaTerminatedNCT03515200Phase 1
- Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic LeukemiaActive, not recruitingNCT03512405Phase 1/2
- Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLLCompletedNCT03502876
- Chronic Lymphocytic Leukemia Responds to Dermal ChelationStatus unknownNCT03495492Not applicable
- Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From IndiaCompletedNCT03476655
- Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaCompletedNCT03472573Phase 1
- Nutritional Status in Children With ALL in GuatemalaCompletedNCT03471416
- Autoimmune Cytopenia and BcR InhibitorsStatus unknownNCT03469895
- CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALLActive, not recruitingNCT03467256Phase 1/2
- De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)Status unknownNCT03462095Not applicable
- Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic LeukemiaCompletedNCT03455517Phase 2
- A Prognostic Tool for Early Stage CLLCompletedNCT03436524
- A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical PracticeCompletedNCT03425591
- Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic MalignanciesWithdrawnNCT03414450Phase 1
- Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCTCompletedNCT03389035Phase 1/2
- Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT03374137
- Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic LeukemiaCompletedNCT03367299Phase 2
- Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHLCompletedNCT03349281Phase 1
- This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With VenetoclaxWithdrawnNCT03343678Phase 1
- Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic LeukemiaStatus unknownNCT03339700Phase 2
- Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/LymphomaCompletedNCT03328104Phase 1
- C-CAR011 Treatment in Subjects With ALL After HSCTStatus unknownNCT03327285Not applicable
- Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaStatus unknownNCT03318770
- Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic LeukemiaStatus unknownNCT03318419Phase 2
- Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical PracticeCompletedNCT03310190
- A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell MalignancyCompletedNCT03301207Phase 1
- An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT03289182
- Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With OfatumumabStatus unknownNCT03280160Phase 2
- DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic LeukemiaTerminatedNCT03265717Phase 2
- A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma SubjectsStatus unknownNCT03265106Phase 1/2
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- Hematotoxicity in Maintenance Therapy of Children With Acute Lymphoblastic LeukemiaCompletedNCT03255668
- New Markers for Minimal Residual Disease in Acute Lymphoblastic LeukemiaStatus unknownNCT03249636
- Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes StudyCompletedNCT03231579
- A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 AberrationsActive, not recruitingNCT03226301Phase 2
- Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)WithdrawnNCT03207542Phase 2
- Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic LeukemiaCompletedNCT03204916
- A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell MalignanciesStatus unknownNCT03191773Phase 1/2
- Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic LeukaemiaWithdrawnNCT03187691Phase 2
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22Status unknownNCT03185494Phase 1/2
- A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic LymphomaCompletedNCT03181126Phase 1
- A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCTCompletedNCT03176849Phase 4
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
- A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma SubjectsStatus unknownNCT03156101Phase 1/2
- Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic LeukemiaActive, not recruitingNCT03155191Phase 1/2
- Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)Active, not recruitingNCT03153202Phase 1/2
- C-X-C Chemokine Receptor 4 in Chronic Lymphocytic LeukemiaStatus unknownNCT03150849
- Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology GroupWithdrawnNCT03141398
- Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALLCompletedNCT03123887
- Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic LeukemiaCompletedNCT03118128Not applicable
- Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/LymphomaStatus unknownNCT03110640Phase 1
- Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic LeukemiaCompletedNCT03109093Phase 2
- huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT03103971Phase 1
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20CompletedNCT03097770Phase 1/2
- Haploidentical Stem Cell Transplantation Using Post-Transplant CyclophosphamideTerminatedNCT03088709Phase 2
- Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell MalignanciesCompletedNCT03076437Phase 1/2
- Genetic Study of Familial Acute Lymphoblastic LeukemiaCompletedNCT03067584
- Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMTWithdrawnNCT03066466Phase 3
- Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in ArgentinaCompletedNCT03059251
- Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid CancersTerminatedNCT03037645Phase 1/2
- Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia (ALL)Status unknownNCT03035344
- CART-19 Cells For MRD Positive CD19+ ALLStatus unknownNCT03027739Phase 2/3
- A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALLStatus unknownNCT03018093Phase 1
- Home-exercise Program for Children and Adolescent Survivors of Acute Lymphoblastic LeukemiaCompletedNCT03005392Phase 1/2
- Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse RiskStatus unknownNCT03000335
- Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximabWithdrawnNCT02993536
- Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersStatus unknownNCT02991638Phase 3
- Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaStatus unknownNCT02981745Phase 1/2
- CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic LeukemiaCompletedNCT02975687Phase 1
- A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT02973191Phase 1/2
- Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant RecoveryCompletedNCT02955043Not applicable
- The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and AdolescentsCompletedNCT02953730Phase 4
- G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Phase 4
- Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic LymphomaTerminatedNCT02928510
- The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).Status unknownNCT02924753Phase 1
- Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATGCompletedNCT02916979Phase 1
- A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and ComorbiditiesCompletedNCT02915224
- Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia PatientsStatus unknownNCT02912754Phase 1/2
- Thiopurine EnhAnced Maintenance TherapyCompletedNCT02912676Phase 1/2
- Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release SyndromeCompletedNCT02906371Phase 1
- Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell LymphomasCompletedNCT02900716Phase 1
- Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 StudyStatus unknownNCT02894645Phase 4
- PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and LymphomaStatus unknownNCT02892695Phase 1/2
- Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALLStatus unknownNCT02888977
- Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease ProgressionCompletedNCT02863718Phase 3
- Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaWithdrawnNCT02861040Phase 1
- Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT02851589Phase 1/2
- Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric OncologyCompletedNCT02847130